An Immunotoxin with Greatly Reduced Immunogenicity by Identification and Removal of B Cell Epitopes

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2008 Aug 6

PMID 18678888

Citations 96

Authors

Masanori Onda

Richard Beers

Laiman Xiang

Satoshi Nagata

Qing-Cheng Wang

Ira Pastan

Affiliations

Soon will be listed here.

Abstract

Recombinant immunotoxins are hybrid proteins composed of an Fv that binds to a tumor antigen fused to a bacterial or plant toxin. Immunotoxin BL22 targets CD22 positive malignancies and is composed of an anti-CD22 Fv fused to a 38-kDa fragment of Pseudomonas exotoxin A (PE38). BL22 has produced many complete remissions in drug-resistant Hairy cell leukemia, where many treatment cycles can be given, because neutralizing antibodies do not form. In marked contrast, only minor responses have been observed in trials with immunotoxins targeting solid tumors, because only a single treatment cycle can be given before antibodies develop. To allow more treatment cycles and increase efficacy, we have produced a less immunogenic immunotoxin by identifying and eliminating most of the B cell epitopes on PE38. This was accomplished by mutation of specific large hydrophilic amino acids (Arg, Gln, Glu, Lys) to Ala, Ser, or Gly. The new immunotoxin (HA22-8X) is significantly less immunogenic in three strains of mice, yet retains full cytotoxic and anti-tumor activities. Elimination of B-cell epitopes is a promising approach to the production of less immunogenic proteins for therapeutic purposes.

Citing Articles

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics.

Sun R, Qian M, Zhang X MAbs. 2024; 16(1):2324836.

PMID: 38512798 PMC: 10962608. DOI: 10.1080/19420862.2024.2324836.

Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin.

Allred C, Gormley C, Venugopal I, Li S, McGuire M, Brown K Commun Biol. 2023; 6(1):60.

PMID: 36650239 PMC: 9845330. DOI: 10.1038/s42003-022-04385-7.

Plant-Derived Type I Ribosome Inactivating Protein-Based Targeted Toxins: A Review of the Clinical Experience.

Flavell D, Flavell S Toxins (Basel). 2022; 14(8).

PMID: 36006226 PMC: 9412999. DOI: 10.3390/toxins14080563.

Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment.

Guerrero-Ochoa P, Ibanez-Perez R, Berbegal-Pinilla G, Aguilar D, Marzo I, Corzana F Biomedicines. 2022; 10(6).

PMID: 35740244 PMC: 9219680. DOI: 10.3390/biomedicines10061223.

in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives.

Pang Z, Gu M, Tang T Front Oncol. 2022; 12:891187.

PMID: 35574361 PMC: 9095937. DOI: 10.3389/fonc.2022.891187.

References

Horton R, Cai Z, Ho S, Pease L . Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques. 1990; 8(5):528-35. View

Reiter Y, Pastan I . Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 1999; 16(12):513-20. DOI: 10.1016/s0167-7799(98)01226-8. View

Kreitman R, Wilson W, Bergeron K, Raggio M, Stetler-Stevenson M, Fitzgerald D . Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001; 345(4):241-7. DOI: 10.1056/NEJM200107263450402. View

Leonard J, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman R . Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005; 23(24):5696-704. DOI: 10.1200/JCO.2005.14.803. View

Onda M, Willingham M, Nagata S, Bera T, Beers R, Ho M . New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res. 2005; 11(16):5840-6. DOI: 10.1158/1078-0432.CCR-05-0578. View

Brinkmann U, Pastan I . Immunotoxins against cancer. Biochim Biophys Acta. 1994; 1198(1):27-45. DOI: 10.1016/0304-419x(94)90004-3. View

Atassi M, Dolimbek B, Hayakari M, Middlebrook J, Whitney B, Oshima M . Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. J Protein Chem. 1996; 15(7):691-700. DOI: 10.1007/BF01886751. View

Hassan R, Lerner M, Benbrook D, Lightfoot S, Brackett D, Wang Q . Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res. 2002; 8(11):3520-6. View

Molineux G . Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy. 2003; 23(8 Pt 2):3S-8S. DOI: 10.1592/phco.23.9.3s.32886. View

10.

De Groot A, Knopp P, Martin W . De-immunization of therapeutic proteins by T-cell epitope modification. Dev Biol (Basel). 2005; 122:171-94. View

11.

Kreitman R, Margulies I, Stetler-Stevenson M, Wang Q, Fitzgerald D, Pastan I . Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res. 2000; 6(4):1476-87. View

12.

Brinkmann U, Pai L, Fitzgerald D, Willingham M, Pastan I . B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A. 1991; 88(19):8616-20. PMC: 52560. DOI: 10.1073/pnas.88.19.8616. View

13.

Collen D, Bernaerts R, Declerck P, De Cock F, Demarsin E, Jenne S . Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. Circulation. 1996; 94(2):197-206. DOI: 10.1161/01.cir.94.2.197. View

14.

Hassan R, Bullock S, Premkumar A, Kreitman R, Kindler H, Willingham M . Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007; 13(17):5144-9. DOI: 10.1158/1078-0432.CCR-07-0869. View

15.

Onda M, Nagata S, Fitzgerald D, Beers R, Fisher R, Vincent J . Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol. 2006; 177(12):8822-34. DOI: 10.4049/jimmunol.177.12.8822. View

16.

Atassi M, Dolimbek B . Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J. 2004; 23(1):39-52. DOI: 10.1023/b:jopc.0000016257.91979.06. View

17.

Reiter Y, Brinkmann U, Lee B, Pastan I . Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol. 1996; 14(10):1239-45. DOI: 10.1038/nbt1096-1239. View

18.

Salvatore G, Beers R, Margulies I, Kreitman R, Pastan I . Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res. 2002; 8(4):995-1002. View

19.

Bugelski P, Treacy G . Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther. 2004; 6(1):10-6. View

20.

Price M, Petrakou E, Sekowski M, Murray A . Immunogenicity of the hydrophilic region of the MUC1 mucin protein core. Oncol Rep. 2011; 4(2):337-9. DOI: 10.3892/or.4.2.337. View